Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/66777
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-Estar06 Água potável e saneamento
09 Indústria, inovação e infraestrutura
Collections
- IOC - Artigos de Periódicos [12980]
Metadata
Show full item record
YELLOW FEVER DISEASE SEVERITY AND ENDOTHELIAL DYSFUNCTION ARE ASSOCIATED WITH ELEVATED SERUM LEVELS OF VIRAL NS1 PROTEIN AND SYNDECAN-1
Author
Sousa, Francielle Tramontini Gomes de
Warnes, Colin M.
Manuli, Erika Regina
Tjang, Laurentia V.
Silva, Pedro Henrique Nascimento Carneiro da
Pinto, Luzia Maria de Oliveira
Ng, Arash
Bhat, Samhita
Zambrana, José Victor
Zanella, Luiz Gonzaga Francisco de Assis Barros D'Elia
Ho, Yeh-Li
Romano, Camila Malta
Beatty, P. Robert
Biering, Scott B.
Kallás, Esper Georges
Sabino, Ester Cerdeira
Harris, Eva
Warnes, Colin M.
Manuli, Erika Regina
Tjang, Laurentia V.
Silva, Pedro Henrique Nascimento Carneiro da
Pinto, Luzia Maria de Oliveira
Ng, Arash
Bhat, Samhita
Zambrana, José Victor
Zanella, Luiz Gonzaga Francisco de Assis Barros D'Elia
Ho, Yeh-Li
Romano, Camila Malta
Beatty, P. Robert
Biering, Scott B.
Kallás, Esper Georges
Sabino, Ester Cerdeira
Harris, Eva
Affilliation
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA / Universidade de São Paulo. Faculdade de Medicina. Instituto de Medicina Tropical. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Laboratório de Investigação Médica. São Paulo, SP, Brasil.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA.
Universidade de São Paulo. Faculdade de Medicina. Instituto de Medicina Tropical. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Laboratório de Investigação Médica. São Paulo, SP, Brasil.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Interações Vírus-Hospedeiros. Rio de Janeiro, RJ, Brasil.
University of California, Berkeley. Department of Molecular and Cell Biology. Division of Immunology and Molecular Medicine. Berkeley, CA, USA.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA.
University of Michigan. School of Public Health. Department of Epidemiology. Ann Arbor, MI, USA.
Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. São Paulo, SP, Brasil.
Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. São Paulo, SP, Brasil.
Universidade de São Paulo. Faculdade de Medicina. Instituto de Medicina Tropical. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Laboratório de Investigação Médica. São Paulo, SP, Brasil.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA / University of California, Berkeley. Department of Molecular and Cell Biology. Division of Immunology and Molecular Medicine. Berkeley, CA, USA.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA.
Universidade de São Paulo. Faculdade de Medicina. Instituto de Medicina Tropical. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Laboratório de Investigação Médica. São Paulo, SP, Brasil / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. São Paulo, SP, Brasil.
Universidade de São Paulo. Faculdade de Medicina. Instituto de Medicina Tropical. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Laboratório de Investigação Médica. São Paulo, SP, Brasil.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA / University of California, Berkeley. Department of Molecular and Cell Biology. Division of Immunology and Molecular Medicine. Berkeley, CA, USA.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA.
Universidade de São Paulo. Faculdade de Medicina. Instituto de Medicina Tropical. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Laboratório de Investigação Médica. São Paulo, SP, Brasil.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Interações Vírus-Hospedeiros. Rio de Janeiro, RJ, Brasil.
University of California, Berkeley. Department of Molecular and Cell Biology. Division of Immunology and Molecular Medicine. Berkeley, CA, USA.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA.
University of Michigan. School of Public Health. Department of Epidemiology. Ann Arbor, MI, USA.
Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. São Paulo, SP, Brasil.
Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. São Paulo, SP, Brasil.
Universidade de São Paulo. Faculdade de Medicina. Instituto de Medicina Tropical. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Laboratório de Investigação Médica. São Paulo, SP, Brasil.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA / University of California, Berkeley. Department of Molecular and Cell Biology. Division of Immunology and Molecular Medicine. Berkeley, CA, USA.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA.
Universidade de São Paulo. Faculdade de Medicina. Instituto de Medicina Tropical. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Laboratório de Investigação Médica. São Paulo, SP, Brasil / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. São Paulo, SP, Brasil.
Universidade de São Paulo. Faculdade de Medicina. Instituto de Medicina Tropical. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Laboratório de Investigação Médica. São Paulo, SP, Brasil.
University of California, Berkeley. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA / University of California, Berkeley. Department of Molecular and Cell Biology. Division of Immunology and Molecular Medicine. Berkeley, CA, USA.
Abstract
Background: Yellow fever virus (YFV) infections are a major global disease concern with high mortality in humans, and as such it is critical to identify clinical correlates of disease severity. While nonstructural protein 1 (NS1) of the related dengue virus is implicated in contributing to vascular leak, little is known about the role of YFV NS1 in severe YF and mechanisms of vascular dysfunction in YFV infections. Methods: Using serum samples from laboratory-confirmed YF patients with severe (n = 39) or non-severe (n = 18) disease in a well-defined hospital observational cohort in Brazil, plus samples from healthy uninfected controls (n = 11), we investigated factors associated with disease severity and endothelial dysfunction. Findings: We found significantly increased levels of NS1, as well as syndecan-1, a marker of vascular leak, in serum from severe YF as compared to non-severe YF or control groups. We also showed that hyperpermeability of endothelial cell monolayers treated with serum from severe YF patients was significantly higher compared to non-severe YF and control groups, as measured by transendothelial electrical resistance (TEER). Further, we demonstrated that YFV NS1 induces shedding of syndecan-1 from the surface of human endothelial cells. Notably, YFV NS1 serum levels significantly correlated with syndecan-1 serum levels, TEER values, and signs of disease severity. Syndecan-1 levels also significantly correlated with clinical laboratory parameters of disease severity, viral load, hospitalization, and death. Interpretation: This study provides further evidence for endothelial dysfunction as a mechanism of YF pathogenesis in humans and suggests serum quantification of YFV NS1 and syndecan-1 as valuable tools for disease diagnosis and/or prognosis.
Share